THERANOSTICS 2016* , ,
Presentations this author is a contributor to:
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT (#15)
4:00 PM
Michael Lassmann
Optimising Peptide Receptor Radionuclide Therapy (PRRT) - (submitted abstracts)
DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy (PRRT) patients with personalised high activities (#7)
11:45 AM
Uta Eberlein
Refining and Defining NET Targets (submitted abstracts)